SciCom
15December2020

ECCO Grant Study Synopsis: Neil Chanchlani

Neil Chanchlani, ECCO Grant Awardee

Understanding the mechanisms of anti-TNF treatment failure in patients with Crohn’s Disease: a proteomic analysis of the PANTS cohort

Neil Chanchlani
© Neil Chanchlani

Aim of research

In the Personalised Anti-TNF Therapy in Crohn’s Disease (PANTS) prospective cohort study, we followed 1,610 patients with Crohn’s Disease treated with infliximab or adalimumab for three years. About one in four patients experienced primary non-response and one-third of initial responders lost response, leaving only one-third in remission at one year.  

 

A limited number of proteomic markers have been implicated in anti-TNF treatment failure, but their relative effects and interactions have not been fully explored. We aim:

  1. To identify novel protein biomarkers linked to intestinal inflammation and immunity that influence pharmacokinetic or pharmacodynamic related primary non-response and non-remission at one year, using two multiplex Olink proteomic panels.
  2. Validate previously postulated protein markers associated with anti-TNF primary non-response and non-remission at one year, including TREM-1, oncostatin M, Vitamin D, ASCA, ANCA and anti-OmpC.

Posted in ECCO News, SciCom, Committee News, Fellowships & Grants Synopsis Reports, Volume 15, Issue 4

15December2020

ECCO Grant Study Synopsis: Simona Bertoni

Simona Bertoni, ECCO Grant Awardee

CCR6 blockade as novel therapeutic strategy against inflammatory bowel disease

Simona Bertoni
© Simona Bertoni

Aim of research

CCL20 and its cognate receptor CCR6 are dysregulated in the colonic mucosa and serum of IBD patients; their genes have been identified as susceptibility genes for IBD and an anti-CCL20 neutralizing antibody has been reported to be beneficial in TNBS-induced colitis.
Our working hypothesis is that blocking the CCL20-CCR6 axis represents a novel and promising approach to IBD therapy by limiting neutrophil recruitment to the inflamed tissues and by restoring the balance of effector/regulatory T cells.
Accordingly, our aim is the preclinical validation of small-molecule CCR6 antagonists as potential drug candidates for the treatment of IBD.

Posted in ECCO News, SciCom, Committee News, Fellowships & Grants Synopsis Reports, Volume 15, Issue 4

15December2020

ECCO Grant Study Synopsis: Marieke Barnhoorn

Marieke Barnhoorn, ECCO Grant Awardee

Unraveling the immunoregulatory effects of local mesenchymal stromal cell therapy in patients with IBD

Marieke Barnhoorn
© Marieke Barnhoorn

Aim of research

Local mesenchymal stromal cell (MSC) therapy is approved for the treatment of Crohn’s Disease-associated perianal fistulas. However, little is known about the mechanism(s) of action of local MSC therapy. In this project we intend to unravel the engraftment and immunoregulatory effects of local MSC therapy in patients with refractory IBD.

Posted in ECCO News, SciCom, Committee News, Fellowships & Grants Synopsis Reports, Volume 15, Issue 4

30September2020

ECCO-AOCC Travel Grant 2020 Report

Arshdeep Singh, Dayanand Medical College and Hospital, Ludhiana, India

Arshdeep Singh
© Arshdeep Singh

ECCO-AOCC Travel Grant Awardee

I accepted the ECCO AOCC Travel Grant 2020 with great pleasure and in all humility. The grant enabled me to visit Helsinki University Central Hospital in Finland between January 13 and March 6, 2020. This gave me the opportunity to increase my knowledge on the management of IBD patients and to gain insight into the faecal microbiota transplant and human microbiome research programme in Finland. At the Hospital District of Helsinki and Uusimaa (HUS), I attended the IBD clinics and IBD inpatient rounds, which greatly enriched my experience. Further, I learned more about IBD endoscopy, including double-balloon enteroscopy and capsule endoscopy for Crohn’s Disease and faecal microbiota transplant (FMT). I intend to deploy this knowledge at our IBD centre to foster further professional growth.

Posted in ECCO News, SciCom, Committee News, Volume 15, Issue 3

30September2020

ECCO Fellowship Study Synopsis: Ferdinando D'Amico

Ferdinando D'Amico, ECCO Fellowship Awardee

Comparative accuracy of the standard Lémann index versus the simplified Lémann index for Crohn’s Disease: a prospective observational cohort study

Ferdinando D'Amico
© Ferdinando D'Amico

Aim of research

Crohn's Disease (CD) is an idiopathic Inflammatory Bowel Disease (IBD) characterised by transmural inflammation of the affected tracts. The uncontrolled inflammation can lead to bowel damage, defined as the onset of strictures, abscesses or fistulas negatively impacting patients' quality of life and outcomes. The Lémann index (LI) is a recently validated tool that was specifically designed to assess the presence of penetrating or stenosing lesions and to quantify their severity. LI is a complex and time-consuming score which is based on imaging [magnetic resonance imaging (MRI)] and endoscopic procedures. Of note, it is mainly used in clinical trials, while its use in clinical practice is limited. Our aim was to develop a simplified LI and to compare the correlation between this simplified LI and the standard LI in assessing bowel damage.

Posted in ECCO News, SciCom, Committee News, Fellowships & Grants Synopsis Reports, Volume 15, Issue 3

30September2020

ECCO Fellowship Study Synopsis: Andres Machicote

Andres Machicote, ECCO Fellowship Awardee

Targeting CD4+ T-cell plasticity in Inflammatory Bowel Diseases

Andres Machicote
© Andres Machicote

Aim of research

Inflammatory Bowel Diseases (IBD) are devastating diseases induced by a breakdown of gut homeostasis, in which CD4+ effector T cells are major mediators of the inflammatory response. Interestingly, CD4+ effector T cells can convert into regulatory T cells, thereby controlling inflammation. However, the forces driving this T-cell plasticity remain largely unexplored, especially in IBD patients. In this regard, changes in the microbiota that can induce different T-cell profiles are commonly observed during IBD. The present proposal aims to elucidate how CD4+ T-cell plasticity can be modulated from a pro-inflammatory towards an anti-inflammatory profile in IBD patients. Our hypothesis is that the microbiota may modulate T cells towards an anti- or pro-inflammatory profile. To address this issue, we aim to analyse T-cell plasticity in IBD patients and mouse IBD models, and to correlate our findings with the microbiota composition. Furthermore, we will study whether antibiotics commonly used to treat IBD affect T-cell plasticity through microbiota-dependent processes.

Posted in ECCO News, SciCom, Committee News, Fellowships & Grants Synopsis Reports, Volume 15, Issue 3

30June2020

Report on the 8th SciCom Workshop at ECCO'20

Sebastian Zeissig, SciCom Chair

Michael Scharl
© ECCO

Marc Ferrante
© ECCO

Sebastian Zeissig
© ECCO

Similarities and differences in the pathogenesis of immune-mediated inflammatory disorders 

This year’s SciCom Workshop focussed on common and distinct pathways in immune-mediated disorders and the application of this knowledge for early disease recognition and interception as well as for the treatment of established disease.

Posted in ECCO News, SciCom, Committee News, Congress News, ECCO'20, Volume 15, Issue 2

30June2020

New SciCom members

Sebastian Zeissig, SciCom Chair


Sebastian Zeissig 
© ECCO

During the ECCO’20 Vienna Congress, the Scientific Committee cordially welcomed Konstantinos Papamichail and Yves Panis as new members of SciCom.

Konstantinos Papamichail has been an ECCO Member since 2007 and has participated in several ECCO Activities, including the 7th ECCO Advanced Course and the ECCO ‘EXIT strategies’ Topical Review. He is a reviewer of the ECCO Grants and also a member of the editorial board of JCC. After completing his PhD in Pharmacology and his GI Fellowship in Greece, Kostas joined the Leuven IBD group as a post-doctoral researcher for 3 years and was also a recipient of an ECCO Fellowship. For the last 5 years he has been working at the Beth Israel Deaconess Medical Center in Boston, where his research has focussed on the role of therapeutic drug monitoring of biologics in IBD. He is the author of numerous publications and his goal is to stimulate scientific interactions in the ECCO Community and beyond and to interact with the other ECCO Committees in order to promote and support national and international IBD research efforts towards the better care of patients with IBD.

Posted in ECCO News, SciCom, Committee News, Volume 15, Issue 2

12March2020

ECCO Fellowships and Grants Report

Sebastian Zeissig, SciCom Chair


Sebastian Zeissig 
© ECCO

One of the main goals of ECCO is to promote IBD-related basic and clinical research as well as to foster interaction and productive collaboration among European research groups working in the IBD field. To achieve this goal, ECCO supports numerous funding schemes with different scopes including ECCO Fellowships, Grants, and Travel Awards.

Posted in ECCO News, SciCom, Committee News, Congress News, ECCO'20, Volume 15, Issue 1

17December2019

N-ECCO Travel Award Report

Rikke Edelbo, N-ECCO Travel Awardee 2019

Rikke Edelbo
© 
Rikke Edelbo

I would like to thank the N-ECCO Committee for awarding me the N-ECCO Travel Award, which was a great financial support and helped me for my studies in Stockholm.

My focus was primarily use of the telephone in patient contacts, patient education, management of newly diagnosed IBD patients and independent nursing activities.

Posted in ECCO News, SciCom, Committee News, N-ECCO, Volume 14, Issue 4